Biogen's Alzheimer's drug gets negative European panel vote
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
The US, Not EU Market is Bulk of Biogen (BIIB) Aduhelm's Value, lecanemab Offers Further Potential Upside - Analyst
November 17, 2021 9:15 AM ESTEarlier today, Biogen Inc. (Nasdaq: BIIB) and Eisai Co., Ltd announces an update on the ongoing review of the Marketing Authorization Application for aducanumab 100 mg/mL concentrate solution for infusion for the treatment of Alzheimers disease by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
Following an oral explanation held at the November meeting... More
